Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation
of metabolic syndrome [1], represents a spectrum of histopathologic
abnormalities ranging from simple steatosis to the more aggressive
non-alcoholic steatohepatitis (NASH), characterised by steatosis, parenchymal
inflammation, hepatocellular ballooning and other evidence of
hepatic injury [2].